Free Trial
NYSE:FNA

Paragon 28 (FNA) Stock Price, News & Analysis

$8.62
-0.03 (-0.35%)
(As of 07/26/2024 ET)
Today's Range
$8.42
$8.79
50-Day Range
$5.71
$8.65
52-Week Range
$5.55
$17.85
Volume
302,736 shs
Average Volume
603,994 shs
Market Capitalization
$715.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.75

Paragon 28 MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
94.3% Upside
$16.75 Price Target
Short Interest
Bearish
18.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.58) to ($0.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.94 out of 5 stars

Medical Sector

761st out of 936 stocks

Surgical & Medical Instruments Industry

84th out of 101 stocks

FNA stock logo

About Paragon 28 Stock (NYSE:FNA)

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

FNA Stock Price History

FNA Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Q1 2024 Paragon 28 Inc Earnings Call
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Unveiling 4 Analyst Insights On Paragon 28
See More Headlines
Receive FNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paragon 28 and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/26/2024
Next Earnings (Confirmed)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Fax
N/A
Employees
574
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.75
High Stock Price Target
$20.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+94.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-47,840,000.00
Pretax Margin
-23.74%

Debt

Sales & Book Value

Annual Sales
$225.44 million
Book Value
$2.15 per share

Miscellaneous

Free Float
70,243,000
Market Cap
$715.04 million
Optionable
Optionable
Beta
0.98
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Albert DaCostaMr. Albert DaCosta (Age 50)
    Co-Founder, Chairman, President & CEO
    Comp: $1.4M
  • Ms. Kristina Wright (Age 47)
    Independent Interim CFO & Director
    Comp: $70k
  • Mr. Robert S. McCormack J.D. (Age 56)
    General Counsel & Secretary
    Comp: $477.53k
  • Mr. Matthew Jarboe (Age 40)
    Chief Commercial Officer
    Comp: $899.92k
  • Mr. Andrew James Hill (Age 40)
    Executive Vice President of Research & Development
    Comp: $306.06k
  • Mr. Jeff Sears
    Vice President of Operations
  • Mr. Erik E Mickelson (Age 42)
    Chief Accounting Officer & Controller
  • Matt Brinckman
    Senior Vice President of Strategy & Investor Relations
  • Ms. Michelle Missal
    VP & Chief Compliance Officer
  • Mr. John Shumaker
    Executive Vice President of Sales - U.S.

FNA Stock Analysis - Frequently Asked Questions

How have FNA shares performed this year?

Paragon 28's stock was trading at $12.43 at the beginning of the year. Since then, FNA shares have decreased by 30.7% and is now trading at $8.62.
View the best growth stocks for 2024 here
.

How were Paragon 28's earnings last quarter?

Paragon 28, Inc. (NYSE:FNA) posted its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.07. The company earned $61.08 million during the quarter. Paragon 28 had a negative trailing twelve-month return on equity of 27.72% and a negative net margin of 24.45%.

When did Paragon 28 IPO?

Paragon 28 (FNA) raised $125 million in an initial public offering on Friday, October 15th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. BofA Securities and Piper Sandler acted as the underwriters for the IPO and Canaccord Genuity, JMP Securities and Needham & Company were co-managers.

Who are Paragon 28's major shareholders?

Paragon 28's top institutional investors include Bank of New York Mellon Corp (0.19%), Valeo Financial Advisors LLC (0.10%) and Nisa Investment Advisors LLC (0.01%). Insiders that own company stock include Mvm Partners Llp, B Ag Bird, Albert Dacosta, Frank S Bono, Matthew Jarboe, Lee Rosenthal, Thomas P Schnettler and Kristina Wright.
View institutional ownership trends
.

How do I buy shares of Paragon 28?

Shares of FNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:FNA) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners